Core Viewpoint - Doximity reported better-than-expected Q3 results but provided lower revenue guidance for Q4 and full-year 2026, leading to a significant drop in stock price during after-hours trading [2][3][4][6] Financial Performance - Doximity's Q3 revenue reached $185.05 million, exceeding estimates of $182.20 million, representing a 10% year-over-year increase [2] - Adjusted earnings for the quarter were 46 cents per share, slightly above the expected 45 cents per share [2] User Engagement and Product Development - The company reported over one million quarterly active prescribers and a record 720,000 users for its workflow products, indicating strong user engagement [3] - Doximity's AI products have gained traction, with over 300,000 users, enhancing the platform's utility [3] Future Guidance - For Q4, Doximity expects revenue between $143 million and $144 million, below the consensus estimate of $150.23 million [4] - The full-year 2026 revenue guidance was narrowed to a range of $642.5 million to $643.5 million from a previous range of $640 million to $646 million [4] Share Repurchase Program - The board of Doximity authorized a share repurchase program to buy back up to $500 million of the company's common stock [4] Stock Performance - Following the earnings report and lowered guidance, Doximity's stock fell by 33.22% in after-hours trading, with shares priced at $22.25 [6]